Risk assessment techniques for acrylamide

Acrylamide and Other Hazardous Compounds in Heat-Treated Foods

Volumn , Issue , 2006, Pages 275-295

  Alexander, Jan ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39149128569     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-84569-011-3.50013-6     Document Type: Chapter

References (89)

1. Abramsson-Zetterberg L. The dose-response relationship at very low doses of acrylamide is linear in the flow cytometer-based mouse micronucleus assay. Mutat. Res 2003, 535:215-222.
2. Ali S.F., Hong J.S., Wilson W.E., Uphouse L.L., Bondy S.C. Effect of acrylamide on neurotransmitter metabolism and neuropeptide levels in several brain regions and upon circulating hormones. Arch Toxicol 1983, 52:35-43.
3. Barber D.S., LoPachin R.M. Proteomic analysis of acrylamide-protein adduct formation in rat brain synaptosomes. Toxicol. Appl. Pharmacol 2004, 201:120-136.
4. Beer M.U., Schlatter J., Dudler V., Zoller O. Fried potatoes and human cancer. Int. J Cancer 2004, 108:634-635.
5. Bergmark E. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Chem. Res. Toxicol 1997, 10:78-84.
6. Bergmark E., Calleman C.J., He F., Costa L.G. Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol. Appl. Pharmacol 1993, 120:45-54.
7. Besaratinia A., Pfeifer G.P. Weak yet distinct mutagenicity of acrylamide in mammalian cells. J Natl. Cancer Inst 2003, 95:889-896.
8. Besaratinia A., Pfeifer G.P. Genotoxicity of acrylamide and glycidamide. J Natl. Cancer Inst 2004, 96:1023-1029.
9. Besaratinia A., Pfeifer G.P. DNA adduction and mutagenic properties of acrylamide. Mutat. Res 2005, 580:31-40.
10. Bjellaas T., Janak K., Lundanes E., Kronberg L., Becher G. Determination and quantification of urinary metabolites after dietary exposure to acrylamide. Xenobiotica 2005, 35:1003-1018.
11. Boettcher M.I., Bolt H.M., Drexler H., Angerer J. Excretion of mercapturic acids of acrylamide and glycidamide in human urine after single oral administration of deuterium-labelled acrylamide. Arch Toxicol 2006, 80:55-61.
12. Bull R.J., Robinson M., Laurie R.D., Stoner G.D., Greisiger E., Meier J.R., Stober J. Carcinogenic effects of acrylamide in Sencar and A/J mice. Cancer Res 1984, 44:107-111.
13. Bull R.J., Robinson M., Stober J.A. Carcinogenic activity of acrylamide in the skin and lung of Swiss-ICR mice. Cancer Lett 1984, 24:209-212.
14. Burek J.D., Albee R.R., Beyer J.E., Bell T.J., Carreon R.M., Morden D.C., Wade C.E., Hermann E.A., Gorzinski S.J. Subchronic toxicity of acrylamide administered to rats in the drinking water followed by up to 144 days of recovery. J Environ. Pathol. Toxicol 1980, 4:157-182.
15. Calleman C.J. The metabolism and pharmacokinetics of acrylamide: implications for mechanisms of toxicity and human risk estimation. Drug Metab. Rev 1996, 28:527-590.
16. Calleman C.J., Bergmark E., Costa L.G. Acrylamide is metabolized to glycidamide in the rat: evidence from hemoglobin adduct formation. Chem. Res. Toxicol 1990, 3:406-412.
17. Calleman C.J., Wu Y., He F., Tian G., Bergmark E., Zhang S., Deng H., Wang Y., Crofton K.M., Fennell T., Costa L.G. Relationships between bio-markers of exposure and neurological effects in a group of workers exposed to acrylamide. Toxicol. Appl. Pharmacol 1994, 126:361-371.
18. Collins J.J., Swaen G.M., Marsh G.M., Utidjian H.M., Caporossi J.C., Lucas L.J. Mortality patterns among workers exposed to acrylamide. J Occup. Med 1989, 31:614-617.
19. Costa L.G., Deng H., Gregotti C., Manzo L., Faustman E.M., Bergmark E., Calleman C.J. Comparative studies on the neuro- and reproductive toxicity of acrylamide and its epoxide metabolite glycidamide in the rat. Neurotoxicology 1992, 13:219-224.
20. Costa L.G., Deng H., Calleman C.J., Bergmark E. Evaluation of the neurotoxicity of glycidamide, an epoxide metabolite of acrylamide: behavioral, neurochemical and morphological studies. Toxicology 1995, 98:151-161.
21. Doerge D.R., Da Costa G.G., Mcdaniel L.P., Churchwell M.I., Twaddle N.C., Beland F.A. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. Mutat. Res 2005, 580:131-141.
22. Doerge D.R., Young J.F., Mcdaniel L.P., Twaddle N.C., Churchwell M.I. Toxicokinetics of acrylamide and glycidamide in B6C3F1 mice. Toxicol. Appl. Pharmacol 2005, 202:258-267.
23. Dybing E., Sanner T. Risk assessment of acrylamide in foods. Toxicol. Sci 2003, 75:7-15.
24. Dybing E., Sanner T., Roelfzema H., Kroese D., Tennant R.W. T25: a simplified carcinogenic potency index: description of the system and study of correlations between carcinogenic potency and species/site specificity and mutagenicity. Pharmacol. Toxicol 1997, 80:272-279.
25. Dybing E., Farmer P.B., Andersen M., Fennell T.R., Lalljie S.P., Muller D.J., Olin S., Petersen B.J., Schlatter J., Scholz G., Scimeca J.A., Slimani N., Törnqvist M., Tuijtelaars S., Verger P. Human exposure and internal dose assessments of acrylamide in food. Food. Chem. Toxicol 2005, 43:365-410.
26. EFSA Opinion of the Scientific Committee on a request from EFSA related to A Harmonised Approach for Risk Assessment of Substances Which are both Genotoxic and Carcinogenic 18-10-2005, http://www.efsa.eu.int/science/sc_commitee/sc_opinions/1201_en.html.
27. Erdreich L.S., Friedman M.A. Epidemiologic evidence for assessing the carcinogenicity of acrylamide. Regul. Toxicol. Pharmacol 2004, 39:150-157.
28. Favor J., Shelby M.D. Transmitted mutational events induced in mouse germ cells following acrylamide or glycidamide exposure. Mutat. Res 2005, 580:21-30.
29. Friedman M. Chemistry, biochemistry, and safety of acrylamide. A review. J Agric. Food. Chem 2003, 51:4504-4526.
30. Friedman M.A., Dulak L.H., Stedham M.A. A lifetime oncogenicity study in rats with acrylamide. Fundam Appl. Toxicol 1995, 27:95-105.
31. Gamboa D.C., Churchwell M.I., Hamilton L.P., Von Tungeln L.S., Beland F.A., Marques M.M., Doerge D.R. DNA adduct formation from acrylamide via conversion to glycidamide in adult and neonatal mice. Chem. Res. Toxicol 2003, 16:1328-1337.
32. Generoso W.M., Sega G.A., Lockhart A.M., Hughes L.A., Cain K.T., Cacheiro N.L., Shelby M.D. Dominant lethal mutations, heritable translocations, and unscheduled DNA synthesis induced in male mouse germ cells by glycidamide, a metabolite of acrylamide. Mutat. Res 1996, 371:175-183.
33. Ghanayem B.I., Mcdaniel L.P., Churchwell M.I., Twaddle N.C., Snyder R., Fennell T.R., Doerge D.R. Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and hemoglobin adducts. Toxicol. Sci 2005, 88:311-318.
34. Ghanayem B.I., Witt K.L., El Hadri L., Hoffler U., Kissling G.E., Shelby M.D., Bishop J.B. Comparison of germ cell mutagenicity in male CYP2E1-null and wild-type mice treated with acrylamide: evidence supporting a glycidamide-mediated effect. Biol. Reprod 2005, 72:157-163.
35. Ghanayem B.I., Witt K.L., Kissling G.E., Tice R.R., Recio L. Absence of acrylamide-induced genotoxicity in CYP2E1-null mice: evidence consistent with a glycidamide-mediated effect. Mutat. Res 2005, 578:284-297.
36. Glatt H., Schneider H., Liu Y. V79-hCYP2E1-hSULT1A1, a cell line for the sensitive detection of genotoxic effects induced by carbohydrate pyrolysis products and other food-borne chemicals. Mutat. Res 2005, 580:41-52.
37. Granath F., Ehrenberg L., Paulsson B., Törnqvist M. Cancer risk from exposure to occupational acrylamide. Occup. Environ. Med 2001, 58:608-609.
38. Hagmar L., Törnqvist M. Inconclusive results from an epidemiological study on dietary acrylamide and cancer. Br. J Cancer 2003, 89:774-775.
39. Hagmar L., Törnqvist M., Nordander C., Rosen I., Bruze M., Kautiainen A., Magnusson A.L., Malmberg B., Aprea P., Granath F., Axmon A. Health effects of occupational exposure to acrylamide using hemoglobin adducts as biomarkers of internal dose. Scand J Work Environ. Health 2001, 27:219-226.
40. Hagmar L., Wirfalt E., Paulsson B., Törnqvist M. Differences in hemoglobin adduct levels of acrylamide in the general population with respect to dietary intake, smoking habits and gender. Mutat. Res 2005, 580:157-165.
41. He F.S., Zhang S.L., Wang H.L., Li G., Zhang Z.M., Li F.L., Dong X.M., Hu F.R. Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ. Health 1989, 15:125-129.
42. IARC Acrylamide. IARC Monogr Eval Carcinog Risks Hum 1994, 60:389-433. International Agency for Research on Cancer. http://www-cie.iarc.fr/htdocs/monographs/vol60/m60-11.htm.
43. Johnson K.A., Gorzinski S.J., Bodner K.M., Campbell R.A., Wolf C.H., Friedman M.A., Mast R.W. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol. Appl. Pharmacol 1986, 85:154-168.
44. Lehning E.J., Balaban C.D., Ross J.F., Reid M.A., LoPachin R.M. Acrylamide neuropathy. I. Spatiotemporal characteristics of nerve cell damage in rat cerebellum. Neurotoxicology 2002, 23:397-414.
45. Lehning E.J., Balaban C.D., Ross J.F., LoPachin R.M. Acrylamide neuropathy. II. Spatiotemporal characteristics of nerve cell damage in brainstem and spinal cord. Neurotoxicology 2003, 24:109-123.
46. Lehning E.J., Balaban C.D., Ross J.F., LoPachin R.M. Acrylamide neuropathy. III. Spatiotemporal characteristics of nerve cell damage in forebrain. Neurotoxicology 2003, 24:125-136.
47. Ling B., Authier N., Balayssac D., Eschalier A., Coudore F. Assessment of nociception in acrylamide-induced neuropathy in rats. Pain 2005, 119:104-112.
48. LoPachin R.M. The changing view of acrylamide neurotoxicity. Neurotoxicology 2004, 25:617-630.
49. LoPachin R.M., Decaprio A.P. Protein adduct formation as a molecular mechanism in neurotoxicity. Toxicol. Sci 2005, 86:214-225.
50. LoPachin R.M., Ross J.F., Lehning E.J. Nerve terminals as the primary site of acrylamide action: a hypothesis. Neurotoxicology 2002, 23:43-59.
51. LoPachin R.M., Balaban C.D., Ross J.F. Acrylamide axonopathy revisited. Toxicol. Appl. Pharmacol 2003, 188:135-153.
52. LoPachin R.M., Barber D.S., He D., Das S. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles. Toxicol. Sci 2006, 89:224-234.
53. Marsh G.M., Lucas L.J., Youk A.O., Schall L.C. Mortality patterns among workers exposed to acrylamide: 1994 follow up. Occup. Environ. Med 1999, 56:181-190.
54. Mucci L.A., Dickman P.W., Steineck G., Adami H.O., Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br. J Cancer 2003, 88:84-89.
55. Mucci L.A., Dickman P.W., Steineck G., Adami H.O., Augustsson K. Reply: Dietary acrylamide and cancer risk: additional data on coffee. British Journal of Cancer 2003, 89:775-776.
56. Mucci L.A., Lindblad P., Steineck G., Adami H.O. Dietary acrylamide and risk of renal cell cancer. Int. J Cancer 2004, 109:774-776.
57. Mucci L.A., Sandin S., Balter K., Adami H.O., Magnusson C., Weiderpass E. Acrylamide intake and breast cancer risk in Swedish women. JAMA 2005, 293:1326-1327.
58. Mucci L.A., Adami H.O., Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int. J Cancer 2006, 118:169-173.
59. Paulsson B., Granath F., Grawe J., Ehrenberg L., Törnqvist M. The multiplicative model for cancer risk assessment: applicability to acrylamide. Carcinogenesis 2001, 22:817-819.
60. Pelucchi C., Franceschi S., Levi F., Trichopoulos D., Bosetti C., Negri E., La Vecchia C. Fried potatoes and human cancer. Int. J Cancer 2003, 105:558-560.
61. Pelucchi C., Galeone C., Levi F., Negri E., Franceschi S., Talamini R., Bosetti C., Giacosa A., La Vecchia C. Dietary acrylamide and human cancer. Int. J Cancer 2006, 118:467-471.
62. Rice J.M. The carcinogenicity of acrylamide. Mutat. Res 2005, 580:3-20.
63. Sanner T., Dybing E., Willems M.I., Kroese E.D. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25. Pharmacol. Toxicol 2001, 88:331-341.
64. Schaumburg H.H., Arezzo J.C., Spencer P.S. Delayed onset of distal axonal neuropathy in primates after prolonged low-level administration of a neurotoxin. Ann. Neurol 1989, 26:576-579.
65. Schulz M.R., Hertz-Picciotto I., Van Wijngaarden E., Hernandez J.C., Ball L.M. Dose-response relation between acrylamide and pancreatic cancer. Occup. Environ. Med 2001, 58:609.
66. Scientific Committee of the Norwegian Food Control Authority Assessment of cancer risk due to acrylamide intake from coffee consumption 13-12-2002, http://www.mattilsynet.no/mattilsynet/multimedia/archive/00018/Risk_assessment_-_co_18500a.pdf.
67. Scientific Committee of the Norwegian Food Control Authority Risk assessment of acrylamide intake from foods with special emphasis on cancer risk 6-6-2002, http://www.snt.mattilsynet.no/nytt/tema/Akrylamid/akrylamid.pdf.
68. Segerbäck D., Calleman C.J., Schroeder J.L., Costa L.G., Faustman E.M. Formation of N-7-(2-carbamoyl-2-hydroxyethyl)guanine in DNA of the mouse and the rat following intraperitoneal administration of [14C]acrylamide. Carcinogenesis 1995, 16:1161-1165.
69. Sobel W., Bond G.G., Parsons T.W., Brenner F.E. Acrylamide cohort mortality study. Br. J Ind. Med 1986, 43:785-788.
70. Spencer P.S., Schaumburg H.H. A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure. Can. J Neurol. Sci 1974, 1:143-150.
71. Spencer P.S., Schaumburg H.H. A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can. J Neurol. Sci 1974, 1:152-169.
72. Spencer P.S., Schaumburg H.H. Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. Neuropathol. Exp. Neurol 1977, 36:276-299.
73. Spencer P.S., Schaumburg H.H. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies. J Neuropathol. Exp. Neurol 1977, 36:300-320.
74. Sumner S.C., MacNeela J.P., Fennell T.R. Characterization and quantitation of urinary metabolites of [1,2,3-13C]acrylamide in rats and mice using 13C nuclear magnetic resonance spectroscopy. Chem. Res. Toxicol 1992, 5:81-89.
75. Sumner S.C., Selvaraj L., Nauhaus S.K., Fennell T.R. Urinary metabolites from F344 rats and B6C3F1 mice coadministered acrylamide and acrylonitrile for 1 or 5 days. Chem. Res. Toxicol 1997, 10:1152-1160.
76. Sumner S.C., Fennell T.R., Moore T.A., Chanas B., Gonzalez F., Ghanayem B.I. Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem. Res. Toxicol 1999, 12:1110-1116.
77. Swiss Federal Office of Public Health Assessment of acrylamide intake by duplicate diet study 2002.
78. Tareke E., Rydberg P., Karlsson P., Eriksson S., Törnqvist M. Acrylamide: a cooking carcinogen?. Chem. Res. Toxicol 2000, 13:517-522.
79. Tareke E., Rydberg P., Karlsson P., Eriksson S., Törnqvist M. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric. Food. Chem 2002, 50:4998-5006.
80. Törnqvist M., Bergmark E., Ehrenberg L., Granath F. Riskbedömning av akrylamid 1998, Chemical Inspectorate, Solna, Sweden.
81. Twaddle N.C., McDaniel L.P., Gamboa D.C., Churchwell M.I., Beland F.A., Doerge D.R. Determination of acrylamide and glycidamide serum toxicokinetics in B6C3F1 mice using LC-ES/MS/MS. Cancer Lett 2004, 207:9-17.
82. Tyl R.W., Friedman M.A. Effects of acrylamide on rodent reproductive performance. Reprod. Toxicol 2003, 17:1-13.
83. Tyl R.W., Marr M.C., Myers C.B., Ross W.P., Friedman M.A. Relationship between acrylamide reproductive and neurotoxicity in male rats. Reprod. Toxicol 2000, 14:147-157.
84. US EPA Acrylamide 7-1-1993, http://www.epa.gov/iris/subst/0286.htm.
85. WHO Application of Risk Analysis to Food Standards Issues 17-3-1995, a Joint FAO/WHO Expert Consultation, Geneva, Switzerland, 13-17 March 1995. http://www.who.int/foodsafety/publications/micro/en/march1995.pdf.
86. WHO Joint FAO/WHO Food Standards Programme Codex Alimentarius Commission Twenty-sixth Session 7-7-2003, Risk analysis policies of the Codex Alimentarius Commission, FAO Headquarters, Rome, Italy, 30 June-7 July 2003. http://www.fao.org/DOCREP/MEETING/006/Y9259E.HTM.
87. WHO Joint FAO/WHO Expert Committee on Food Additives sixty-fourth meeting 17-2-2005, Rome 8-17 February 2005. 7-17. http://www.who.int/ipcs/food/jecfa/summaries/summary_report_64_final.pdf.
88. WHO About Risk Analysis in Food 7-3-2006, http://www.who.int/foodsafety/micro/riskanalysis/en/.
89. Wise L.D., Gordon L.R., Soper K.A., Duchai D.M., Morrissey R.E. Developmental neurotoxicity evaluation of acrylamide in Sprague-Dawley rats. Neurotoxicol. Teratol 1995, 17:189-198.